Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety
Compugen Ltd. (NASDAQ:CGEN – Get Rating) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 1,890,000 shares, a decline of 5.5% from the March 15th total of 2,000,000 shares. Based on an average daily trading volume, of 429,600 shares, the days-to-cover ratio is […]
Graphite Bio (NASDAQ:GRPH – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Graphite Bio has a beta of 0.01, […]
Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.
Antonetti Capital Management LLC raised its stake in shares of Compugen Ltd. (NASDAQ:CGEN – Get Rating) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 583,277 shares of the biotechnology company’s stock after buying an additional […]